MedTrace Logo

Augmentation in Tx-resistant OCD: an Open Label Trial

NCT00590642 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2009-12-01

No results posted yet for this study

Summary

This study examines the use of Acamprosate (Campral(R)) in the treatment of Obsessive Compulsive Disorder (OCD). The treatment of this condition is difficulty and a large percentage of patients fail to respond to medications and have residual symptoms. Such patients are referred to as having treatment resistant OCD.

Conditions

  • Obsessive Compulsive Disorder

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Creighton University

    lead OTHER

Principal Investigators

  • Sriram Ramaswamy, MD · Creighton University

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00590642 on ClinicalTrials.gov